Johns Hopkins Center for Psychedelic and Consciousness Research

Wondering what clinicians should know about psychedelic-assisted treatments? tinyurl.com/hopkinscme Join our upcoming CME/CE course for an evidence-based introduction to psychedelic medicine—designed to help clinicians engage with patients, understand new research, and prepare for the future of psychedelic-assisted care. 📚 Earn up to 6.5 CME/CE credits. 📅 March 27, 2026, Online 9am-4pm EDT

New findings from a pilot randomized trial of psilocybin for smoking cessation are now published in JAMA Network Open. In this trial, smokers who received psilocybin had over 6 times greater odds of prolonged abstinence 6 months post-treatment than those who received nicotine patch (40.5% psilocybin vs. 10% patch), suggesting therapeutic potential. https://lnkd.in/drR9TbZd

Thanks Dr. Charles Nichols for presenting at the CPCR journal club! Watch Dr. Nichols' full presentation on using preclinical models to investigate the therapeutic potential of psychedelics. https://lnkd.in/e83R_wDD

We are thrilled to announce our brand new Continuing Medical Education course, taught by CPCR faculty! The course is designed for anyone interested in learning more about psychedelic medicine, including physicians, advanced practice providers, and mental health providers. Participants can earn up to 6.5 CME/CE credits while gaining the knowledge to thoughtfully engage with patients and prepare for a future of psychedelic assisted care. March 27, 2026 | 9am - 4pm EDT | Live Online Register at https://lnkd.in/ePStV-yb

Ready for a weekend of science at the International Society for Research on Psychedelics (ISRP) with presentations from Dr. Sandeep Nayak, Sean Goldy, PhD, Nathan Sepeda, Brian Winston, and Michael Levine

New pilot study shows two doses of psilocybin reduced symptom burden by ~40% in people with post-treatment Lyme disease (PTLD), with improvements in pain, fatigue, sleep, and mood lasting up to 6 months. Findings are still very preliminary, but suggests psilocybin may be a new avenue for treating PTLD and possibly similar illnesses. https://lnkd.in/emvZtpBr

New pilot study from Johns Hopkins finds psilocybin-assisted treatment was associated with significant and sustained benefits in post-treatment Lyme disease, including improved mood, fatigue, sleep, pain, and quality of life for up to 6 months. More research is needed to confirm.  https://lnkd.in/e9m648AH   

Huge congratulations to Dr. Albert Garcia-Romeu, PhD who was recently named a Frontiers of Science Fellow by the National Academy of Sciences! https://lnkd.in/eEtWY_eu

A new review in Psychiatric Times synthesizes adverse event data for psilocybin, MDMA, ketamine, and ibogaine, highlighting that risk profiles differ meaningfully across compounds and that current reporting practices remain inconsistent. Clearer differentiation at the compound level will be essential as psychedelic research and clinical access continue to expand. https://lnkd.in/e5UqKBVj

Dr. Fred Barrett co-authored a new paper examining key challenges in conducting rigorous clinical trials with classical psychedelics, including issues like expectancy effects, blinding, and study design. As psychedelic therapies move closer to FDA approval, addressing these scientific and ethical complexities is critical to ensuring treatments are both safe and evidence-based. This work reflects our commitment to advancing thoughtful, methodologically sound research that can responsibly shape the future of mental health care.